What amount sold does Cardax Pharmaceuticals Inc report in Form D filings?

The latest linked filings report $550K sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Cardax Pharmaceuticals Inc's most recent SEC filing?

Cardax Pharmaceuticals Inc's most recent Form D filing was on 2010-09-28.

How many investors does Cardax Pharmaceuticals Inc have?

The most recent Form D filing lists 4 investor(s).

What type of securities does Cardax Pharmaceuticals Inc offer?

Cardax Pharmaceuticals Inc's SEC Form D filings indicate debt offerings.

Cardax Pharmaceuticals Inc

CIK: 0001408223·Biotechnology·Honolulu, HI·Corporation·Founded 2006

Reported Sold

$550,000

Total Filings

Identified Offerings

Last Filed

Sep 28, 2010

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Sep 28, 2010Form D — New notice

Reported sold: $550,000 · Target: $2,000,000

Rule 506·4 investors

Fundraising Profile

Exemptions

Rule 506

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$550,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

David G. Watumull

Related Person

Appears on 1 filing

Nicholas Mitsakos

Related Person

Appears on 1 filing

Frederic J. Pashkow

Related Person

Appears on 1 filing

Frank Herringer

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Sep 28, 2010	New	$2,000,000	$550,000	4

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

511 Therapeutics, Inc.

Biotechnology

Offering target: $1,000,000

Filed Oct 30, 2026